Are there generic versions of Panitumumab?

In 2017, Amgen announced that the U.S. Food and Drug Administration (FDA) had approved a supplemental biologics license application for panitumumab for the treatment of patients with wild-type RAS (wild-type in both KRAS and NRAS, as determined by an FDA-approved trial) metastatic colorectal cancer (mCRC) as a first-line treatment in combination with FOLFOX and as a monotherapy for disease progression after fluoropyrimidine therapy.

Panitumumab is the first and only fully human monoclonal anti-epidermal growth factor receptor (EGFR) antibody approved by the FDA for this patient population. The fully human properties of panitumumab may result in a safety profile with lower rates of infusion reactions, antigenicity, and anaphylaxis, and these attributes are currently being investigated in clinical trials, with pivotal clinical studies of panitumumab as third-line monotherapy in patients with colorectal cancer ongoing. Panitumumab is available as an intravenous infusion (drip) at a recommended dose of 6 mg per kilogram of body weight once every two weeks. The generally recommended infusion time is approximately 60 minutes. If severe skin reactions occur, the dose may need to be adjusted. If the reaction does not improve, treatment should be discontinued.

It is understood that the original version of panitumumab has not yet been launched in China, and therefore it has not been covered by medical insurance. The price of the Hong Kong original version of panitumumab sold in Hong Kong, China100mg/5mL may be around RMB 9,000 (the price may fluctuate due to exchange rates). There are currently no generic drugs of Panitumumab on the market. If a patient has a need to purchase Panitumumab, please consult a medical consultant for specific prices and more drug information.